Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director

Arbutus Biopharma Corp (ABUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
08/03/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 , in combination with pegylated interferon alfa-2a, in a Phase 2a clinical trial, was generally well tolerated and appears to result in continued HBsAg declines in some patients First patient dosed in additional arm of Phase 2a clinical trial combining imdusiran, VTP-300, NA therapy and nivolumab – advancing towards goal of further stimulating host HBV-associated immunity Cash runway into the first quarter of 2025 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 03, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutica...",
"Corporate Presentation"
07/13/2023 4 Rewolinski Melissa (Director) has filed a Form 4 on Arbutus Biopharma Corp
Txns: Granted 110,000 options to buy @ $0
07/13/2023 3 Rewolinski Melissa (Director) has filed a Form 3 on Arbutus Biopharma Corp
07/12/2023 4 Sims Karen (Chief Medical Officer) has filed a Form 4 on Arbutus Biopharma Corp
Txns: Granted 153,640 options to buy @ $2.26, valued at $347.2k
07/12/2023 3 Sims Karen (Chief Medical Officer) has filed a Form 3 on Arbutus Biopharma Corp
07/12/2023 4 Naftzger J. Christopher (General Counsel and CCO) has filed a Form 4 on Arbutus Biopharma Corp
Txns: Granted 500,000 options to buy @ $0
07/12/2023 3 Naftzger J. Christopher (General Counsel and CCO) has filed a Form 3 on Arbutus Biopharma Corp
07/12/2023 8-K Quarterly results
07/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arbutus Appoints Two New Executives Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement litigations. Both Dr. Sims and Mr. Naftzger will report directly to William Collier, Arbutus President and Chief Executive Offic..."
06/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023 WARMINSTER, Pa., June 07, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted for poster presentations at the European Association for the Study of the Liver Congress 2023 taking place June 21 - 24, 2023 in Vienna, Austria. The accepted abstracts for poster presentations are as follows: Abstract Number: 4112 Title: Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection Presenter: Prof. Man-Fung Yuen Presentati..."
05/30/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "EXHIBIT 10.1 ARBUTUS BIOPHARMA CORPORATION 2016 OMNIBUS SHARE AND INCENTIVE PLAN"
05/26/2023 4 HENRIQUES RICHARD C JR (Director) has filed a Form 4 on Arbutus Biopharma Corp
Txns: Granted 55,000 options to buy @ $0
05/26/2023 4 BURGESS DANIEL D (Director) has filed a Form 4 on Arbutus Biopharma Corp
Txns: Granted 55,000 options to buy @ $0
05/26/2023 4 MANCHESTER KEITH S (Director) has filed a Form 4 on Arbutus Biopharma Corp
Txns: Granted 55,000 options to buy @ $0
05/26/2023 4 Torti Frank (Director) has filed a Form 4 on Arbutus Biopharma Corp
Txns: Granted 55,000 options to buy @ $0
05/26/2023 4 Meyers James R (Director) has filed a Form 4 on Arbutus Biopharma Corp
Txns: Granted 55,000 options to buy @ $0
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
04/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech"
03/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161 Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first subject has been dosed in the Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of AB-161, Arbutus’ oral RNA destabilizer. AB-161 is being developed for use in an all-oral combination regimen to potentially provide a functional cure for patients with hepatitis B virus . “We are pleased to move AB-161 into Phase 1 clinical development,” said William Collier, President and C..."
03/02/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Quarterly results
Docs: "Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for oral PD-L1, AB-101, and oral RNA Destabilizer, AB-161, expected in the second half of 2023 Initiate Phase 1 clinical trial for oral M pro coronavirus candidate, AB-343, expected in the second half of 2023 Strengthened financial position – cash runway into Q4 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., March 02, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific vi...",
"Corporate Presentation"
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 SC 13G BlackRock Inc. reports a 5.6% stake in Arbutus Biopharma Corp
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy